STOCK TITAN

Contineum Therapeutics, Inc. - $CTNM STOCK NEWS

Welcome to our dedicated page for Contineum Therapeutics news (Ticker: $CTNM), a resource for investors and traders seeking the latest updates and insights on Contineum Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Contineum Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Contineum Therapeutics's position in the market.

Rhea-AI Summary
Contineum Therapeutics, Inc. announces pricing of IPO, offering 6,875,000 shares of Class A common stock at $16.00 per share, expecting gross proceeds of $110.0 million. Shares to trade on Nasdaq under symbol 'CTNM'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Contineum Therapeutics, Inc.

Nasdaq:CTNM

CTNM Rankings

CTNM Stock Data

372.19M
23.40M
United States of America